Barry J. Linder, MD, MS President & CEO Eyedetec Medical, Inc.
Understanding Dry Eye Disease (DED)
"85% of patients who have DED do not have a lack of tears, they have MGD (Meibomian Gland Dysfunction). And MGD is treatable. That means we have been treating 85% of patients wrong for 50 years!!!" Daniel Durrie, MD
DED Impacts Quality of Life & Vision, and is a Global Eye Health Challenge
Key Challenges in DED – The Problems
Transformational Solution
Transformational Solution – Novel Technology
Eye Lipid Mobilizer™ (ELM)
Treatment of Moderate to Severe DED
Continuity of care from Practice to Home
Telehealth Enabled
Patented Mechanisms of Action
Scalable Continuity of Care
Cost Effective Efficient to Meet Growing Demand
Global Market Approaching $7.8 Billion by 2026 (350M Patients)
Eyedetec will Initially Focus on USA Market of $2.4B (30M Patients) – Growing 6.9% CAGR
REFRACTIVE CATARACT SURGERY
$4B Global Intraocular Lens Market Excellent Refractive Cataract Outcomes Depend on Treating DED
CONTACT LENS INTOLERANCE 38%
$14B Global Contact Lens Market
INCREASED INCIDENCE WITH AGING POPULATION
25% of Population >50 y.o.
SCREEN TIME & DECREASED BLINKING
Coming DED tsunami!
Excellent Refractive Cataract Outcomes Depend on Treating DED
Coming DED tsunami!
Eyedetec Understands the DED Market
EyeGiene® Insta-Warmth™
Treatment of Mild DED
Reusable Eye Mask
Disposable Warming Wafers
Controlled Heat
Clinical validation (Singapore Eye Research Institute)